

The Copenhagen Stock Exchange
Nikolaj Plads 6
DK-1067 Copenhagen K.

October 16, 2006

Stock Exchange Notification No. 11/2006

India investigation completed – Cheminova will provide more information about corporate social responsibility activities

With reference to Cheminova's previous press releases concerning the situation in India (December 20, 2005, and June 19, June 20 and July 6, 2006) which can be found at www.cheminova.dk, please find information below about the results of the investigations carried out in India.

After the TV programme "Når tilbud dræber", the media coverage during the recent months and discussions with several of our stakeholders, we have decided that in future detailed information will be provided about non-financial matters in the Cheminova group.

Further details about the information contained in the present press release are provided on the Cheminova website in the form of a number of links to underlying documentation.

Health of people living near the factory

On September 17, 2006, an independent medical examination was carried out of villagers with health problems living in the village of Sanjali close to Cheminova's factory in Panoli. The examination was organised by the Indian Medical Association, Ankleshwar Branch as a so-called Medical Camp sponsored by Cheminova via the Panoli Industries Association. The event had been announced in advance by loud-speaker vans both in Sanjali and in the nearby villages of Kharod and Bakrol, and free bus transport was organised from these villages. A total of 9 doctors were present, including a specialist in skin diseases.


Out of a total population in excess of 15,000 in the three villages, 463 patients accepted the offer of a free examination and free treatment. In none of the 463 cases examined (323 from Sanjali and 140 from the other villages) does the report identify Cheminova as the cause or contributory cause of any illness. The conclusion of the medical report points to poor sanitary conditions and poor hygiene and generally poor living standards as the most important causes of the diseases examined.

Subsequently, a skin specialist examined one of the two patients presented in the TV programme as suffering from skin problems. Mr M. Suleman's illness was diagnosed as a skin disease which is seen in the population in general and which cannot be attributed to exposure to chemicals. This is documented by the doctor's note.

Cancer study

In order to shed further light on the cancer issue Cheminova has, as promised, initiated the independent gathering of data and an investigation comprising interviews with approx. 2,000 patients in two cancer hospitals which are situated in geographical areas with different cultural, climatic, nutritional and social conditions. The two hospitals are non-profit organisations which attract poor patients from a large catchment area. One of the hospitals is the hospital in Bikanir which was featured in the TV programme.

Postboks 9
DK-7620 Lemvig
Tel: +45 7010 7030
Fax: +45 7010 7031
E-mail: investor@auriga.dk
Internet:
www.auriga-industries.com



The report concludes that there are no significant differences between the occurrence of the most common cancers in patients from the rural and urban populations in the two areas. The investigation has, of course, been limited and is not an in-depth epidemiological study.

However, it is known by the approving authorities that monocrotophos and the other products manufactured and sold by Cheminova in India are not carcinogenic.

Following the report on the results of the investigation of the health of the people living near the factory and the cancer investigation, we consider the investigation of the allegations made in the TV programme "Når tilbud dræber" as having been concluded.

Monocrotophos to be phased out as a Class I product

In Denmark, Cheminova's sales of the insecticide monocrotophos in India have given rise to criticism from various sides. The product, which played a major role in the green revolution which made India self-sufficient in foods, continues to be the most frequently used insecticide in India. It plays a decisive role in the competitive production of cotton and rice.

Cheminova has decided to phase out the current monocrotophos formulation (WHO Class I) in the course of 2009.

In accordance with the FAO's Code of Conduct, Cheminova has for several years been working on the development of a less toxic formulation of monocrotophos which offers occupational health and safety benefits during the storage, transport and handling of the product. Cheminova is currently conducting several hundred field tests with the new formulation. The extensive trials are expected to be completed by the end of 2007. An application for registration of the product will be submitted to the authorities in February 2008, and approval is expected to be granted by the end of that year. Once approval has been granted, Cheminova will from the 2009 season be able to market this safer version of the product (WHO Class II).

Cheminova will continue and intensify its endeavours to inform Indian farmers how to handle and use pesticides correctly.


Annual reporting

Cheminova has in recent months been in touch with several stakeholders and has observed a need for more and better information about the safety, health and environmental aspects of the company's activities.

Cheminova will seek to meet this need by publishing an annual Corporate Social Responsibility report, not only on the environmental situation at the factory in Denmark, but also on the factory in India. Cheminova will report on all important safety, health-related, environmental and use-related issues, providing a status on the results achieved so that anybody interested can follow aims and results within these important areas.

The report will be structured to cover the main areas of human rights, employee rights, the environment and anti-corruption.

The first report will be published in April 2007 and will take account of the special characteristics of an agrochemical company such as Cheminova. In the first report, Cheminova will among other things describe the Responsible Care activities and the environmental and occupational health and safety certifications under the two ISO 14001 and OHSAS 18001 standards which are expected to be granted to the Danish factory at the end of the year.



In the ongoing endeavours to improve reporting, Cheminova will draw inspiration both from developments within the UN's Global Compact report and from other international reporting within the field of corporate social responsibility.

The reporting within the above-mentioned non-financial areas will also describe the initiatives implemented by Cheminova in its endeavours to live up to the FAO's Code of Conduct regarding the distribution and use of plant protection products, including in particular endeavours in the developing countries to replace chemicals which are hazardous to human health (WHO Class I) with less hazardous ones.

Cheminova currently manufactures and sells Class I formulations with three active substances, methyl parathion, DDVP and monocrotophos. Today methyl parathion is sold in 11 countries, with the USA as by far the biggest market. In three countries it is sold exclusively as a Class II microcapsule product, in three countries only as a Class I product and in five countries both products are sold. DDVP is sold in a couple of countries and monocrotophos is sold only in India. In addition, Cheminova has limited sales of Class I products manufactured by other companies. The reporting will primarily focus on status and activities aimed at reducing the use of these products in developing countries.

AURIGA INDUSTRIES A/S

Mogens Nehen-Hansen
President
Auriga Industries A/S

Bjørn Albinus
President
Cheminova A/S

Enquiries concerning this notification should be addressed to President Bjørn Albinus on tel. +45 9690 9690.